PT - JOURNAL ARTICLE AU - Budhiraja, Sandeep AU - Tarai, Bansidhar AU - Jain, Dinesh AU - Aggarwal, Mona AU - Indrayan, Abhaya AU - Das, Poonam AU - Mishra, RS AU - Bali, Supriya AU - Mahajan, Monica AU - Kirtani, Jay AU - Tickoo, Rommel AU - Soni, Pankaj AU - Nangia, Vivek AU - Lall, Ajay AU - Kishore, Nevin AU - Jain, Ashish AU - Singh, Omender AU - Singh, Namrita AU - Kumar, Ashok AU - Saxena, Prashant AU - Dewan, Arun AU - Aggarwal, Ritesh AU - Mehra, Mukesh AU - Jain, Meenakshi AU - Nakra, Vimal AU - Sharma, B D AU - Pandey, Praveen Kumar AU - Singh, YP AU - Arora, Vijay AU - Jain, Suchitra AU - Chhabra, Ranjana AU - Tuli, Preeti AU - Boobna, Vandana AU - Joshi, Alok AU - Aggarwal, Manoj AU - Gupta, Rajiv AU - Aneja, Pankaj AU - Dhall, Sanjay AU - Arora, Vineet AU - Chugh, Inder Mohan AU - Garg, Sandeep AU - Mittal, Vikas AU - Gupta, Ajay AU - Jyoti, Bikram AU - Sharma, Puneet AU - Bhasin, Pooja AU - Jain, Shakti AU - Singhal, RK AU - Bhasin, Atul AU - Vardani, Anil AU - Pal, Vivek AU - Pande, Deepak Gargi AU - Gulati, Tribhuvan AU - Nayar, Sandeep AU - Kalra, Sunny AU - Garg, Manish AU - Pande, Rajesh AU - Bag, Pradyut AU - Gupta, Arpit AU - Sharma, Jitin AU - Handoo, Anil AU - Burman, Purabi AU - Gupta, Ajay Kumar AU - Choudhary, Pankaj Nand AU - Gupta, Ashish AU - Gupta, Puneet AU - Joshi, Sharad AU - Tayal, Nitesh AU - Gupta, Manish AU - Khanna, Anita AU - Kishore, Sachin AU - Sahay, Shailesh AU - Dang, Rajiv AU - Mishra, Neelima AU - Sekhri, Sunil AU - Srivastava, Rajneesh Chandra AU - Agrawal, Mitali Bharat AU - Mathur, Mohit AU - Banwari, Akash AU - Khetarpal, Sumit AU - Pandove, Sachin AU - Bhasin, Deepak AU - Singh, Harpal AU - Midha, Devender AU - Bhutani, Anjali AU - Kaur, Manpreet AU - Singh, Amarjit AU - Sharma, Shalini AU - Singla, Komal AU - Gupta, Pooja AU - Sagar, Vinay AU - Dixit, Ambrish AU - Bajpai, Rashmi AU - Chachra, Vaibhav AU - Tyagi, Puneet AU - Saxena, Sanjay AU - Uniyal, Bhupesh AU - Belwal, Shantanu AU - Aier, Imliwati AU - Singhal, Mini AU - Khaduri, Ankit TI - Secondary infections modify the overall course of hospitalized COVID-19 patients: A retrospective study from a network of hospitals across North India AID - 10.1101/2021.09.27.21264070 DP - 2021 Jan 01 TA - medRxiv PG - 2021.09.27.21264070 4099 - http://medrxiv.org/content/early/2021/09/29/2021.09.27.21264070.short 4100 - http://medrxiv.org/content/early/2021/09/29/2021.09.27.21264070.full AB - Introduction SARS-CoV-2 infection increases the risk of secondary bacterial and fungal infections and contributes to adverse outcomes. The present study was undertaken to get better insights into the extent of secondary bacterial and fungal infections in Indian hospitalized patients and to assess how these alter the course of COVID-19 so that the control measures can be suggested.Methods This is a retrospective, multicentre study where data of all RT-PCR positive COVID-19 patients was accessed from Electronic Health Records (EHR) of a network of 10 hospitals across 5 North Indian states, admitted during the period from March 2020 to July 2021.The data included demographic profile of patients, clinical characteristics, laboratory parameters, treatment modalities, and outcome in those with secondary infections (SIs) and those without SIs. Spectrum of SIS was also studied in detail.Results Of 19852 RT-PCR positive SARS-CO2 patients admitted during the study period, 1940 (9.8%) patients developed SIs. Patients with SIs were 8 years older on average (median age 62.6 years versus 54.3 years; P<0.001) than those without SIs. The risk of SIs was significantly (p < 0.001) associated with age, severity of disease at admission, diabetes, ICU admission, and ventilator use.The most common site of infection was urinary tract infection (UTI) (41.7%), followed by blood stream infection (BSI) (30.8%), sputum/BAL/ET fluid (24.8%), and the least was pus/wound discharge (2.6%). As many as 13.4% had infections with more than organism and 34.1% patients had positive cultures from more than one site. Gram negative bacilli (GNB) were the commonest organisms (63.2%), followed by Gram positive cocci (GPC) (19.6%) and fungus (17.3%). Most of the patients with SIs were on multiple antimicrobials – the most commonly used were the BL-BLI for GNBs (76.9%) followed by carbapenems (57.7%), cephalosporins (53.9%) and antibiotics carbapenem resistant entreobacteriace (47.1%). The usage of emperical antibiotics for GPCs was in 58.9% and of antifungals in 56.9% of cases, and substantially more than the results obtained by culture.The average stay in hospital for patients with SIs was twice than those without SIs (median 13 days versus 7 days). The overall mortality in the group with SIs (40.3%) was more than 8 times of that in those without SIs (4.6%). Only 1.2% of SI patients with mild COVID-19 at presentation died, while 17.5% of those with moderate disease and 58.5% of those with severe COVID-19 died (P< 0.001). The mortality was highest in those with BSI (49.8%), closely followed by those with HAP (47.9%), and then UTI and SSTI (29.4% each). The mortality rate where only one microorganism was identified was 37.8% and rose to 56.3% in those with more than one microorganism. The mortality in cases with only one site of infection was 28.8%, which steeply rose to 62.5% in cases with multiple sites of infection. The mortality in diabetic patients with SIs was 45.2% while in non-diabetics it was 34.3% (p < 0.001).Conclusions Secondary bacterial and fungal infections can complicate the course of almost 10% of COVID-19 hospitalised patients. These patients tend to not only have a much longer stay in hospital, but also a higher requirement for oxygen and ICU care. The mortality in this group rises steeply by as much as 8 times. The group most vulnerable to this complication are those with more severe COVID-19 illness, elderly, and diabetic patients. Varying results in different studies suggest that a region or country specific guideline be developed for appropriate use of antibiotics and antifungals to prevent their overuse in such cases. Judicious empiric use of combination antimicrobials in this set of vulnerable COVID-19 patients can save lives.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding has been included in this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional Ethics Committee, Max Super Speciality Hospital (A unit of Devki Devi Foundation), Address: Service Floor, Office of Ethics Committee, East Block, next to Conference Room, Max Super Speciality Hospital, Saket (A unit of Devki Devi Foundation), 2, Press Enclave Road, Saket, New Delhi 110017 vide ref. no. BHR/RS/MSSH/DDF/SKT-2/IEC/IM/21-24 dated 7th September 2021. The IEC provided no objection and approved the publication of this manuscript.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesdata of all RTPCR positive COVID19 patients was accessed from Electronic Health Records (EHR) of a network of 10 hospitals across 5 North Indian states, admitted during the period from March 2020 to July 2021.